Our perspectives
in one place
Topic
Selected filters
ClearNews
See allTwelfth meeting of the Intergovernmental Negotiating Body (INB)
On 4 November 2024 in Geneva, IFPMA delivered a statement at the twelfth meeting of the Intergovernmental Negotiating Body (INB).
Read moreConclusion of COP16 Negotiations on Multilateral Mechanism for Benefit-Sharing of DSI
On the conclusion of the COP16 negotiations on proposals to include digital sequence information (DSI) within the scope of the Convention of Biodiversity (CBD), IFPMA delivered a Statement
Read more74th WHO Regional Committee for Europe: Harnessing innovation for public health in the WHO European Region 2025-2030
On 31 October 2024 in Copenhagen, Denmark, IFPMA delivered a statement at the 74th WHO Regional Committee for Europe on harnessing innovation for public health in the WHO European Region 2025-2030.
Read more74th WHO Regional Committee for Europe: Framework for resilient and sustainable health systems in the WHO European Region
On 31 October 2024 in Copenhagen, Denmark, IFPMA and EFPIA delivered a statement at the 74th Regional Committee for Europe on the framework for resilient and sustainable health systems in the WHO European Region.
Read more74th WHO Regional Committee for Europe: WHO/Europe Access to Novel Medicines Platform
On 29 October 2024 in Copenhagen, Denmark, IFPMA and EFPIA delivered a statement at the 74th WHO Regional Committee for Europe on the WHO/Europe Access to Novel Medicines Platform.
Read moreOpening statement at COP 16: Multilateral mechanism (MLM) for digital sequence information (DSI)
On 21 October 2024 in Cali, Colombia, IFPMA delivered an opening statement at the 16th meeting of the Conference of the Parties to the Convention on Biological Diversity.
Read morePublications
See allThe value of prevention for economic growth and the sustainability of healthcare, social care and welfare systems (The European House – Ambrosetti)
Read moreSustainable access to effective antibiotics
In a new position paper, IFPMA explores some of the challenges in ensuring access to safe and quality-assured antibiotics and propose a set of policy changes for consideration.
Read moreThe Value of Reference Agency Assessment Reports in Enabling Regulatory Reliance
Access to information, including the assessment documents of reference national regulatory agencies (NRA), is a key enabler of regulatory risk-based decision making. It promotes an understanding of what was reviewed by the reference NRA, provides a rationale for decision making and promotes confidence and trust. The Centre for Innovation in Regulatory Science (CIRS) has published...
Read moreExpert insights
See allForum unites key stakeholders to discuss Ghana’s health economy
Read moreTime to lead the charge: The pharmaceutical industry’s role in combating NCDs
Read moreCelebrating a decade of ethical collaboration: An international consensus of healthcare leaders looks to the future
Read moreResources
See allOur Ethos in Action – Decision-Making Framework Toolkit
IFPMA has developed a Five-Phase Decision-Making Framework, grounded in the IFPMA Ethos or value system, to help companies make decisions that balance business objectives and ethical considerations to meet patient needs and the expectations of the medical community, regulators, and society.
Read moreFebruary 2024: Impact of a waiver of intellectual property rights for COVID-19 therapeutics
As discussions on an extension of a waiver of intellectual property (IP) rights on COVID-19 therapeutics continue, latest evidence and data published today explains what the adverse impact of a waiver may be on the entire innovation ecosystem and the consequences it may have on industry’s ability to fight future pandemics.
Read more